Evidence type/study | Summary of results | Notes | |
Antimicrobial agents | |||
General | Cochrane review,99 other systematic review93 | Generally beneficial (see text) | Resistance and nebulised tobramycin poorly tolerated in some95 |
Macrolides16 | Randomised non-placebo trial (n = 12) azithromycin for 6 months vs usual treatment | Exacerbations significantly reduced in treatment arm compared with non-treatment arm (16 vs 5) | |
Nebulised tobramycin94 | Double blind crossover RCT in 30 patients with P aeruginosa, 6 months each | Number and days of admissions less in tobramycin arm but no difference in number of exacerbations | Resistance and nebulised tobramycin poorly tolerated in some95 |
Anti-inflammatory agents | |||
Indomethacin100 | Cohort study, 25 mg three times daily for 28 days | Reduction in peripheral neutrophil chemotaxis; no change in sputum albumin, elastase, myeloperoxidase or exacerbation | |
Mucolytics | |||
Bromhexine | Cochrane review101 | Studies only in acute phase | Not universally available |
rhDNAse | Systematic review101 102 | Increased exacerbation rate | |
Airway clearance | |||
Chest physiotherapy | Cochrane review103 | Two small trials on bronchiectasis, exacerbation rate not reported | |
Inhaled hyperosmolar agents | Cochrane review,104 additional RCT (non-blinded) using 7% HS105 | Neither study reported on exacerbation rates | |
Asthma therapies | |||
Inhaled corticosteroids (ICS) | Cochrane review104 and double blind RCT using 500 μg fluticasone twice daily15 | Reduced exacerbation rate only seen in those with P aeruginosa infection.15 No significant effect of ICS in Cochrane review104 | Limited applicability in children-high dose ICS and children less likely to have P aeruginosa |
Oral corticosteroids | Cochrane review106 | No RCTs | No data* |
Anticholinergics | Cochrane review107 | No RCTs | No data* |
β2-agonists | Cochrane review108 109 | No RCTs | No data* |
LTRA | Cochrane review110 | No RCTs | No data* |
Physical training | Cochrane review111 and RCT112 which was included in Cochrane as an abstract (data changed) | No data on exacerbation | Pulmonary rehabilitation improves exercise tolerance, no additional advantage of simultaneous inspiratory muscle training |
Environmental modification | No data* | Assumed beneficial (see text) | |
Oxygen (domiciliary) | No data as sole therapy* | Consider data from COPD showing benefit in survival but no effect on exacerbation113 114 | |
Surgery | Cochrane review115 | No RCTs. Cohort studies suggest beneficial in selected cases.1 Annual exacerbation rate reduced from 5.9 to 2.3 | Reduction in exacerbation rate similar in medically treated group.116 Adverse events of surgery115 117 118 |
Vaccines | No data* | Advocated as vaccines prevent respiratory infections119 | |
Ventilatory assistance | |||
NPPV† | Retrospective case controlled study on NPPV with oxygen120 | Reduced hospitalisation rate, no difference in mortality | No effect on survival |
Retrospective study using NPPV with oxygen121 | Reduced hospitalisation days, improved QOL | Paco2 stabilised after NIV but no change on Pao2 | |
Model of care | |||
Nurse-led | Cochrane review122 | No difference in infective exacerbations but increase in hospitalisations in nurse-led care compared with doctor-led care | Increased healthcare cost implications |
Sputum surveillance | No data* | Suggestions that this should be done123 (frequency undefined) | Chronic infection or colonisation prevalent (see text) |
Psychosocial | No data* | 34% have depression, anxiety or both74 |
COPD, chronic obstructive pulmonary disease; HS, hypertonic saline; LTRA, leucotriene receptor antagonist; NPPV, non-invasive positive pressure ventilation; QOL, quality of life; RCT, randomised controlled trial.
*No other data specific to exacerbation based on single reviewer search on PubMed (March 2006).
†A review article suggested that non-invasive positive pressure ventilation is probably beneficial in reducing exacerbation days/episodes in those with chronic respiratory failure, although the data are scarce.113